Executive Management

Paul Jacobson has served as our co-founder, Chief Executive Officer, and on our board of directors since 2010. He has also served as co-founder, Chief Executive Officer and on the board of directors for Company subsidiaries, including Thorne Research Inc., Health Elements, LLC and WellnessFX, Inc. since 2010. Mr. Jacobson is also the co-founder and Chief Executive Officer for Onegevity Health, LLC, which is now a division of our company. In addition, he has served on the board of directors for Tecton Group, LLC since 2020, and from 2017 to 2020, he served on the board of directors for Drawbridge Health, Inc. Prior to joining our company, Mr. Jacobson was on the board of directors for Progenics Pharmaceuticals and a Partner and Co-head of the Liquid Capital Markets Department at Goldman Sachs. He holds an M.B.A. from Washington University in Saint Louis and a B.A. in English and Economics from Vanderbilt University. We believe Mr. Jacobson is qualified to serve on our board of directors due to his extensive history with us and his business experience in investment banking and finance.

Thomas McKenna has served as our Chief Operating Officer and on our board of directors since 2010. Before joining our company, he was the Chief Operating Officer of Diversified Natural Products, Inc. Prior to that, he spent most of his career at Bristol-Myers Squibb in a variety of operational roles. Mr. McKenna holds an M.B.A. in Accounting from the Fox School of Business at Temple University and a B.S. in Finance from Fairfield University. We believe that Mr. McKenna is qualified to serve on our board of directors due to his extensive history with us, finance experience and education.

Will McCamy has served as President for Thorne Research, Inc. and on the board of directors for Health Elements, LLC, since 2010, both of which are our subsidiaries. Prior to joining our company, Mr. McCamy served as co-founder and President for Xymogen, Inc. Mr. McCamy has over 26 years of experience in the nutritional sciences industry, specifically focusing on the healthcare professional segment but recently expanding into consumer-driven initiatives and sport performance. Mr. McCamy holds a B.S. in Finance from University of Florida.

Scott Wheeler has served as Chief Financial Officer for us and our subsidiaries, Thorne Research, Inc., HEU Holding Company and Health Elements, LLC, since 2011. Prior to joining our Company, Mr. Wheeler served as Chief Financial Officer for Pulmuone Foods USA from 2009 to 2011 and Chief Financial Officer for Monterey Gourmet Foods, Inc., a publicly traded company, from 2003 through 2009. He holds an M.B.A. from Golden Gate University and a B.S. in Accounting from Brigham Young University. We expect that Mr. Wheeler will retire from his position as Chief Financial Officer of the Company during 2022, but will continue to consult with the Company through the end of 2022.

Michelle Crow has served as our Chief Marketing Officer since November 2017. She has also served on the board of directors for Akreto, Inc. since October 2020. Prior to becoming our Chief Marketing Officer, she held numerous positions from 2012 to October 2017 at our subsidiary Thorne Research Inc., including Vice President of Marketing, Assistant Vice President of Marketing, Director of Marketing, Manager of Operations, and Marketing Associate. Ms. Crow holds an M.B.A. in Marketing and Strategy from the Leonard N. Stern School of Business at New York University and a B.A. in Philosophy and Spanish from Duke University.

Scott Hurth has served as our Chief Technology Officer since 2014. He has also served on the board of directors for Akreto, Inc. since October 2020. Prior to his current roles, he co-founded Greydin, LLC, an information technology consulting firm and has held various positions with Amazon. He holds a B.S. in Computer Science from the University of Wisconsin Eau Claire.

Stephen Phipps has served as our Chief Innovation Officer since January 2021. Prior to his current role, he held numerous positions from 2015 to 2021 at our subsidiary Thorne Research, Inc., including Chief Innovation Officer, Vice President of Research and Development and Director of Clinical Programs. Mr. Phipps is also a member of the American Association of Naturopathic Physicians and the Naturopathic Academy of Primary Care Physicians, and was a practicing Naturopathic physician before joining our Company. He holds a N.D. in Naturopathic Medicine from Bastyr University, a Ph.D. in Pharmaceutical Sciences from the University of Florida and a B.S. in Botany from the University of Florida.

Dr. Nathan Price has served as Co-Chief Executive Officer for Onegevity Health, LLC, from November 2020 until its merger with our Company in March 2021. Post-merger, Dr. Price will be the Chief Executive Officer of Onegevity, a division of our company. Dr. Price has also served on the Board of Directors of Health and Environmental Sciences, a non-profit, since 2018. Since 2017, Dr. Price has co-led the Hood-Price Integrated Lab for Systems Biomedicine with biotechnology pioneer Lee Hood. Prior to his current roles, Dr. Price served as co-founder and Director of Arivale Inc. from 2014 to 2019. He has also served on many advisory boards, including Roche (Personalized Healthcare Division), Providence St. Joseph Health, Sera Prognostics, Navican, Basepaws, Trelys and the Novo Nordisk Foundation Center for Biosustainability. Dr. Price holds a Ph.D. in Bioengineering from the University of California, San Diego, an M.S. in Bioengineering from the University of California, San Diego and a B.S. in Chemical Engineering from Brigham Young University.

Dr. Bodi Zhang has served as Chief Science Officer for Onegevity Health, LLC from January 2018 until its merger with our company in March 2021. Post-merger, Dr. Zhang continues in the role as Chief Science Officer of Onegevity, a division of our company. Prior to his current role, Dr. Zhang served as Vice President, Corporate and Medical Strategy from January 2015 to 2018, and as General Manager, Strategic Alliance from January 2013 to 2015. Prior to joining our company, Dr. Zhang worked at Deallus Group, a global healthcare consultancy. Prior to the Deallus Group, Dr. Zhang was a Research Assistant Professor of Pharmacology at Tufts University, Boston. As a scientist, Bodi’s research focused on autoimmune diseases and published top-tier research publications, including in Proceedings of the National Academy of Sciences, The Journal of Allergy and Clinical Immunology and Nature Reviews. Dr. Zhang holds a Ph.D in Pharmacology and Biochemistry from Tufts University, Boston, an M.P.H in healthcare management from Harvard University, Boston and a M.D. from Peking University, China.

La Vonda Williams has served as Chief Financial Officer for Onegevity Health, LLC, which is now a division of our company, since September 2019. Before joining that entity, she served as Vice President of Equity Derivatives Operations at Goldman Sachs from 2014 to 2019. Prior to that, Ms. Williams served as Chief Operating Officer for Solaire Generation, Inc. from 2009 to 2010. Ms. Williams has spent nearly 20 years in finance and operations in a series of executive roles at early-stage startups, as well as operations, sales and underwriting positions at leading investment banks. She holds an M.B.A. from Stanford University and a B.S. in Mechanical Engineering from Harvard University.